



GOVERNOR'S OFFICE OF CRIME PREVENTION, YOUTH, AND VICTIM SERVICES

Opioid Use Disorder and Examinations

Data Definitions and Reporting Guide

This *Opioid Use Disorder and Examinations: Reporting Guide* provides guidance on the submission of opioid use disorder screening, evaluation, and treatment program information, as required by House Bill 116 (2019). Created with input from stakeholders, this guide serves to identify the reporting requirements, a definition for required data elements, and instruction on the submission of all opioid use disorder screening, evaluation, and treatment program information.

To quickly access one of these areas, please select from the following list.

Introduction	2
Data Definitions	3
Reporting Period	4
Reporting Guide	4

Introduction

House Bill 116 (2019) establishes programs for opioid use disorder screening, evaluation, and treatment (specifically medications to treat opioid use disorder (MOUD)) in local correctional facilities and in the Baltimore Pretrial Complex.¹ It also requires the program to begin in four counties (Howard, Montgomery, Prince George's, and St. Mary's) by January 1, 2020, apply to six additional counties by October 1, 2021, and then expand to include all counties and the Baltimore Pretrial Complex by January 2023. In addition, the Act requires the State to fund the programs, and it establishes requirements for screening and treatment. Furthermore, and in accordance with § 9-603(j) of the Correctional Services Article, the Governor's Office of Crime Prevention, Youth, and Victim Services² (Office) shall report data from individual local correctional facilities to the General Assembly by November 1, 2020, and annually thereafter, as it relates to the following:

1. The number of inmates diagnosed with:
 - a. A mental health disorder;
 - b. An opioid use disorder;
 - c. A non-opioid substance use disorder; and
 - d. A dual diagnosis of mental health and substance use disorder;
2. The number and cost of assessments for inmates in local correctional facilities, including the number of unique inmates examined;
3. The number of inmates who were receiving medication or MOUD for opioid use disorder immediately prior to incarceration;
4. The type and prevalence of medication or MOUD for opioid use disorder provided;
5. The number of inmates diagnosed with opioid use disorder;
6. The number of inmates for whom medication and MOUD for opioid use disorder was prescribed;
7. The number of inmates for whom medication and MOUD was prescribed and initiated for opioid use disorder;
8. The number of medications and MOUD for opioid use disorder provided according to each type of medication and medication-assisted treatment options;
9. The number of inmates who continued to receive the same medication or MOUD for opioid use disorder as the inmate received prior to incarceration;

¹ Maryland General Assembly. (2019). [*House Bill 116 \(2019\). Public Health - Correctional Services - Opioid Use Disorder Examinations and Treatment*](#). Maryland Department of Legislative Services. (2019). [*The 90 Day Report: A Review of the 2019 Legislative Session*](#).

² Maryland General Assembly. (2020). [*Chapter 11. Acts of 2020*](#). In March 2020, the Governor's Office of Crime Control and Prevention was renamed the Governor's Office of Crime Prevention, Youth, and Victim Services.

10. The number of inmates who received a different medication or MOUD for opioid use disorder compared to what the inmate received prior to incarceration;
11. The number of inmates who initiated treatment with medication or MOUD for opioid use disorder who were not being treated for opioid use disorder prior to incarceration;
12. The number of inmates who discontinued medication or MOUD for opioid use disorder during incarceration;
13. A review and summary of the percent of days, including the average percent, median percent, mode percent, and interquartile range of percent, for inmates with opioid use disorder receiving medication or MOUD for opioid use disorder as calculated overall and stratified by other factors, such as type of treatment received;
14. The number of inmates receiving medication or MOUD for opioid use disorder prior to release;
15. The number of inmates receiving medication or MOUD prior to release for whom the facility had made a pre-release reentry plan;
16. A review and summary of practices related to medication and MOUD for opioid use disorder for inmates with opioid use disorder before October 1, 2019;
17. A review and summary of pre-release planning practices relative to inmates diagnosed with opioid use disorder prior to, and following, October 1, 2019; and
18. Any other information requested by the Maryland Department of Health related to the administration of the provisions under this section.

Data Definitions

The following definitions must be used when submitting opioid use disorder screening, evaluation, and treatment program information:

Inmate means an individual confined within a local correctional facility.³

Medication means a medication approved by the federal Food and Drug Administration for the treatment of opioid use disorder.⁴

Medications for Opioid Use Disorder (MOUD) (also known as medication-assisted treatment) means the use of medication, in combination with counseling and behavioral health therapies, to provide a holistic approach to the treatment of opioid use disorder.⁵

³ Maryland General Assembly. (2019). [*House Bill 116 \(2019\). Public Health - Correctional Services - Opioid Use Disorder Examinations and Treatment*](#).

⁴ Ibid.

⁵ Maryland General Assembly. (2019). [*House Bill 116 \(2019\). Public Health - Correctional Services - Opioid Use Disorder Examinations and Treatment \(Fiscal and Policy Note\)*](#).

Opioid use disorder means a medically diagnosed problematic pattern of opioid use that causes significant impairment or distress.⁶

Peer recovery specialist means an individual who has been certified by an entity approved by the Maryland Department of Health for the purpose of providing peer support services, as defined under § 7.5-101(n) of the Health - General Article.⁷

Reporting Period

All jails must compile and submit their data in the described format (see below) no later than August 1 of each year, to cover the reporting period of the prior State fiscal year (July 1 - June 30). Because the data is requested per individual, in order to follow their movement through the program, all data entries should occur on an ongoing basis.

Reporting Guide

All opioid use disorder screening, evaluation, and treatment program information can be entered into an excel spreadsheet template which includes data elements required by [House Bill 116 \(2019\)](#). A description of the data elements, to include the available selections for each, is provided below. It is important to note that a ~~striketrough~~ of a data element indicates that it is duplicative of another data element and therefore is not needed.

#1. The number of inmates diagnosed with: a mental health disorder; an opioid use disorder; a non-opioid substance use disorder; and a dual diagnosis of mental health and substance use disorder.

The template will designate four columns to capture this data element, to include the following:

ID#: A unique identifier must be provided for each inmate who has been diagnosed with a mental health disorder, an opioid use disorder, a non-opioid substance use disorder, and a dual diagnosis of mental health and substance use disorder. If an inmate is diagnosed multiple times during the reporting period, and/or if the diagnosis changes, include the same ID# as his/her first diagnosis. This information will be used to track the total number of inmates diagnosed and the total number of diagnoses. Please note that all inmates diagnosed with one of the items listed above must be accounted for.

⁶ Ibid.

⁷ Maryland General Assembly. (2019). [House Bill 116 \(2019\). Public Health - Correctional Services - Opioid Use Disorder Examinations and Treatment](#).

Diagnosis: Use the “dropdown” menu to select the diagnosis for each inmate.

- Mental health disorder
- Opioid use disorder
- Non-opioid substance use disorder
- Dual diagnosis of mental health and substance use disorder

Opioid Use Disorder: If *Opioid use disorder* is selected for the diagnosis, write out the applicable type (e.g., Amphetamines, Barbiturates, Buprenorphine, Benzodiazepines, Cocaine, Methamphetamines, MDMA, MOP (Opiates), Methadone, Oxycodone, PCP, THC, Fentanyl, Tramadol, K2).

Non-Opioid Substance Use Disorder: If *Non-opioid substance use disorder* is selected for the diagnosis, write out the applicable type (e.g., ETG (Alcohol)). It is important to note that if a non-opioid substance use disorder is entered, no additional information is necessary for the remaining data elements (i.e., data element #2 through data element #15) for this inmate.

#2. The number and cost of assessments for inmates in local correctional facilities, including the number of unique inmates examined.

The template will designate one column to capture this data element, to include the following:

Assessments: Provide the number of assessments for each inmate.⁸ If an inmate is assessed multiple times during the reporting period, include the same ID# as his/her first assessment. This information will be used to track the total number of inmates assessed and the total number of assessments.

Please note that applicable information relating to the cost of assessments (e.g, mental health assessments, opioid screening, medical screening, etc.) can be emailed to the Office, using the provided excel spreadsheet template, on an annual basis.

#3. The number of inmates who were receiving medication or MOUD for opioid use disorder immediately prior to incarceration.

⁸ Maryland General Assembly. (2019). [*House Bill 116 \(2019\). Public Health - Correctional Services - Opioid Use Disorder Examinations and Treatment \(Fiscal and Policy Note\)*](#). The fiscal note provides the following definition for screening: “Each local correctional facility must conduct an assessment of the mental health and substance use status of each inmate using evidence-based screenings and assessments to determine if the medical diagnosis of an opioid use disorder is appropriate and if MAT is appropriate. If a required assessment indicates opioid use disorder, an evaluation of the inmate must be conducted by a specified health care practitioner; and information must be provided to the inmate describing medications used in MAT. In addition, MAT must be available to an inmate for whom such treatment is determined to be appropriate, as specified.”

The template will designate one column to capture this data element, to include the following:

Treatment prior to incarceration: Use the “dropdown” menu to select if the inmate was receiving medication or MOUD for opioid use disorder immediately prior to incarceration. By selecting *Yes*, this indicates that the inmate was receiving medication or MOUD at the time of his/her placement in jail and/or 30 days prior to incarceration.

- Yes
- No

Please note that [House Bill 116 \(2019\)](#) does not specify a timeframe for *immediately*. Because of this, and for the purpose of data entry, the term *immediately* refers to *within the past 30 days prior to incarceration*.

#4. The type and prevalence of medication or MOUD for opioid use disorder provided.

The template will designate five columns to capture this data element, to include the following:

Type of treatment: Use the “dropdown” menu to select the type of treatment for opioid use disorder.

- Methadone
- Naltrexone
- Suboxone/Buprenorphine
- Other
- None, inmate declined
- None, inmate released prior to receiving program services

Other: If *Other* is selected for the type of treatment, write out the applicable type.

Route of administration: Use the “dropdown” menu to select the route of administration. Please refer to the [Medication-Assisted Treatment for Opioid Use Disorder in Jails and Prisons: A Planning & Implementation Toolkit](#) (pages 12-13) and [Expanding Access to Medications for Opioid Use Disorder in Corrections and Community Settings: A Roadmap for States to Reduce Opioid Use Disorder for People in the Justice System](#) (page 15) for more information.

- Oral
- Injection

Frequency of administration: Use the “dropdown” menu to select the frequency in which the medication or MOUD is administered.

- Daily
- Monthly

Treatment start date: Provide the date in which the treatment started, based on a MM/DD/YYYY format. This represents the date in which the inmate received his/her first dose.

~~#5. The number of inmates diagnosed with opioid use disorder.~~

Please note that data element #1 encompasses data element #5 and therefore is not needed.

#6. The number of inmates for whom medication and MOUD for opioid use disorder was prescribed.

The template will designate one column to capture this data element, to include the following:

Prescribed treatment: Use the “dropdown” menu to select if the inmate was prescribed medication or MOUD for opioid use disorder. Please note that all inmates prescribed treatment for opioid use disorder at intake must be accounted for.

- Yes
- No

#7. The number of inmates for whom medication and MOUD was prescribed and initiated for opioid use disorder.

The template will designate one column to capture this data element, to include the following:

Initiated treatment: Use the “dropdown” menu to select if medication and MOUD was initiated by the inmate.

- Yes
- No
- Not applicable (if no was selected in #6)

~~#8. The number of medications and MOUD for opioid use disorder provided according to each type of medication and medication-assisted treatment options.~~

Please note that data element #4 encompasses data element #8 and therefore is not needed.

#9. The number of inmates who continued to receive the same medication or MOUD for opioid use disorder as the inmate received prior to incarceration.

The template will designate one column to capture this data element, to include the following:

Continued same treatment: Use the “dropdown” menu to select if the inmate continued to receive the same medication or MOUD prior to incarceration.

- Yes
- No
- Not applicable

#10. The number of inmates who received a different medication or MOUD for opioid use disorder compared to what the inmate received prior to incarceration.

The template will designate one column to capture this data element, to include the following:

Received different treatment: Use the “dropdown” menu to select if the inmate received a different medication or MOUD prior to incarceration.

- Yes
- No
- Not applicable

~~**#11. The number of inmates who initiated treatment with medication or MOUD for opioid use disorder who were not being treated for opioid use disorder prior to incarceration.**~~

Please note that data element #3 encompasses data element #11 and therefore is not needed.

#12. The number of inmates who discontinued medication or MOUD for opioid use disorder during incarceration.

The template will designate one column to capture this data element, to include the following:

Discontinued treatment: Use the “dropdown” menu to select if the inmate discontinued treatment during incarceration.

- Yes, voluntary
- Yes, involuntary
- No
- Not applicable

Please note that inmates who continue, discontinue, and/or re-start medication or MOUD for opioid use disorder will be captured based on their ID#.

#13. A review and summary of the percent of days, including the average percent, median percent, mode percent, and interquartile range of percent, for inmates with opioid use disorder receiving medication or MOUD for opioid use disorder as calculated overall and stratified by other factors, such as type of treatment received.

The template will designate three columns to capture this data element, to include the following:

Intake date: Provide the date in which the inmate entered the jail, based on a MM/DD/YYYY format.

Release date: Provide the date in which the inmate was released from the facility, based on a MM/DD/YYYY format. Leave blank if the inmate is still incarcerated.

Treatment end date: Provide the date in which the treatment ended, based on a MM/DD/YYYY format. Leave blank if the inmate is still in treatment.

Please note that entries for data element #4 (*Treatment start date*) will be used in addition to entries for data #13 to identify the statistical measures for inmates receiving medication or MOUD (medication-assisted treatment) for opioid use disorder.

~~**#14. The number of inmates receiving medication or MOUD for opioid use disorder prior to release.**~~

Please note that data elements #4 and #13 encompass data element #14 and therefore is not needed.

#15. The number of inmates receiving medication or MOUD prior to release for whom the facility had made a pre-release reentry plan.

The template will designate one column to capture this data element, to include the following:

Reentry plan: Use the “dropdown” menu to select if the inmate received a pre-release reentry plan.

- Yes
- No
- Not applicable

#16. A review and summary of practices related to medication and MOUD for opioid use disorder for inmates with opioid use disorder before October 1, 2019.

Please note that applicable information can be emailed to the Office.

#17. A review and summary of pre-release planning practices relative to inmates diagnosed with opioid use disorder prior to, and following, October 1, 2019.

Please note that applicable information can be emailed to the Office.

#18. Any other information requested by the Maryland Department of Health related to the administration of the provisions under this section.

Please note that no additional information was requested by the Maryland Department of Health.